The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Dena Battle
Consulting or Advisory Role - Exelixis; Pfizer
Other Relationship - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Merck; Pfizer
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Nazli Dizman
Consulting or Advisory Role - Vivreon Biosciences
 
Luis A Meza
No Relationships to Disclose
 
Daniela V. Castro
No Relationships to Disclose
 
Ameish Govindarajan
No Relationships to Disclose
 
Benjamin D. Mercier
No Relationships to Disclose
 
Neal Shiv Chawla
No Relationships to Disclose
 
Alex Chehrazi-Raffle
No Relationships to Disclose
 
Abhishek Tripathi
Honoraria - Cardinal Health; Targeted Oncology; Urology times
Consulting or Advisory Role - Deka Biosciences; EMD Serono; Exelixis; Exelixis; Foundation Medicine; Genzyme; Pfizer; Seagen
Research Funding - Aravive (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Exelixis (Inst); Pfizer (Inst); WindMIL (Inst)
 
Sandy Liu
Honoraria - Eisai; EMD Serono; Exelixis; Merck; Seagen; Seagen
Consulting or Advisory Role - Exelixis; Exelixis; Seagen; Seagen; Seagen
Speakers' Bureau - EMD Serono; Exelixis; Exelixis; Seagen
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Merck Serono; Pfizer; Sanofi/Aventis
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Michael D. Staehler
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EMD Serono; EUSA Pharma; Exelixis; Incyte; Ipsen; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Apogepha; Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Exelixis; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Novartis; Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; EMD Serono; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pfizer
 
Sumanta Monty Pal
Research Funding - Allogene Therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - crispr therapeutics; Roche